CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 469 enrolled
Drug / intervention
LY2216684 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00420004
NCT00420004Phase 2Completed
CompareCT.gov

A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor (NERI), in the Treatment of Major Depression

Eli Lilly and Company·interventional·Posted Jan 9, 2007·Updated Apr 27, 2018

In Brief

A Phase 2 clinical trial evaluating LY2216684, Placebo, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 469 participants across 7 sites in 2 countries.

Detailed Summary

This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesRomania, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 9, 2007
Enrollment StartDec 1, 2006
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.5 years ago

Interventions

LY2216684drug

3-mg and 6-mg tablets

Placebodrug

Escitalopramdrug

10-mg capsules